In addition, it has been reported that PRKG2 inhibits EGF-induced MAPK/c-Jun N-terminal kinase (JNK) signal transduction in human breast cancer cells (Lan et al., 2012) and also inhibits the activation of EGFR and HER2 in gastric cancer cells (Zhu et al., 2016; Lan et al., 2019). This evidence concerns the gene ERBB2 and breast carcinoma.